Involution of PTEN-null endometrial glands with progestin therapy
- 1 March 2004
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 92 (3) , 1008-1013
- https://doi.org/10.1016/j.ygyno.2003.11.026
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia—precursor of endometrial cancerGynecologic Oncology, 2003
- Diagnosis of premalignant endometrial diseaseJournal of Clinical Pathology, 2002
- Apoptosis May Be an Early Event of Progestin Therapy for Endometrial HyperplasiaGynecologic Oncology, 2000
- Long-Term Continuous Combined Hormone Replacement Therapy in the Prevention of Postmenopausal Bone Loss: A Comparison of High- and Low-Dose Estrogen-Progestin RegimensOsteoporosis International, 2000
- I. Histopathology of Genetically Defined Endometrial Precancers*International Journal of Gynecological Pathology, 2000
- Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial PrecancersJNCI Journal of the National Cancer Institute, 2000
- Changes in Endometrial PTEN Expression throughout the Human Menstrual CycleJournal of Clinical Endocrinology & Metabolism, 2000
- Down-Regulation of Bcl-2 Is a Potential Marker of the Efficacy of Progestin Therapy in the Treatment of Endometrial HyperplasiaGynecologic Oncology, 1999
- Long-term effect of megestrol acetate in the treatment of endometrial hyperplasiaAmerican Journal of Obstetrics and Gynecology, 1983
- Progestin therapy in endometrial hyperplasiaGynecologic Oncology, 1974